Favipiravir (T-705), a novel viral RNA polymerase inhibitor

By Y. Furuta, B. Gowen, Kazumi Takahashi, K. Shiraki, D. Smee, D. Barnard. Antiviral Research, 2013

997 citations recorded by the source corpus.

Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. It is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5′-triphosphate (RTP). Its antiviral effect is attenuated by the addition of purine nucleic acids, indicating the viral RNA polymerase mistakenly recognizes favipiravir-RTP as a purine nucleotide. Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options. A Phase III clinical evaluation of favipiravir for influenza therapy has been completed in Japan and two Phase II studies have been completed in the United States. In addition to its anti-influenza activity, favipiravir blocks the replication of many other RNA viruses, including arenaviruses (Junin, Machupo and Pichinde); phleboviruses (Rift Valley fever, sandfly fever and Punta Toro); hantaviruses (Maporal, Dobrava, and Prospect Hill); flaviviruses (yellow fever and West Nile); enteroviruses (polio- and rhinoviruses); an alphavirus, Western equine encephalitis virus; a paramyxovirus, respiratory syncytial virus; and noroviruses. With its unique mechanism of action and broad range of antiviral activity, favipiravir is a promising drug candidate for influenza and many other RNA viral diseases for which there are no approved therapies.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/7125e67bd4362da6aff6859e76f20b04dfb4dbc4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Minghui Yang
Dongjing Liu
Jun Chen
Chenguang Shen
D. Shu
Junxia Xia
X. Liao
Yu-tong Gu

Citations in the corpus

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study (2020, positive): “These findings suggest that FPV has significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance, as compared with LPV/RTV. FPV, which is known as a prodrug, is a novel RNA-dependent RNA polymerase (RdRp) inhibitor, which has been shown to be effective in th”